false 0001762303 0001762303 2022-05-12 2022-05-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2022

 

 

AVITA Medical, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39059   85-1021707

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

28159 Avenue Stanford, Suite 220, Valencia, CA 91355   661.367.9170
(Address of principal executive offices, including Zip Code)   (Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

   

Trading

Symbol(s)

   

Name of each exchange

on which registered
Common Stock, par value $0.0001 per share    RCEL    The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition; Item 7.01 Reg Fd Disclosure.

On May 12, 2022, AVITA Medical, Inc. (the “Company”), reported financial results for its first quarter 2022, and certain other business updates. A webcast of the event is available on the Company’s website under Investor Events and Presentations. In conjunction with the report, the Company released a press release attached hereto as Exhibit 99.1 and a slide deck attached hereto as Exhibit 99.2.

The information under Item 2.02, Item 7.01, Exhibit 99.1, and Exhibit 99.2 is preliminary, has not been audited, and is subject to change. The information disclosed is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933 except as expressly set forth by specific reference in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.

   

Description of Exhibit
99.1    AVITA Medical Reports First Quarter 2022 Financial Results
99.2    Company Update
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 17, 2022

 

AVITA MEDICAL, INC.
By:  

/s/ Donna Shiroma
Name:   Donna Shiroma
Title:   General Counsel
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From May 2022 to Jul 2022 Click Here for more Avita Medical Charts.
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Avita Medical Charts.